News

Article

ASCRS 2024: Nordic Pharma to present data on canalicular gel for treatment of dry eye

Author(s):

The company’s Lacrifill canalicular gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

(Image Credit: AdobeStock/Kryuchka Yaroslav)

(Image Credit: AdobeStock/Kryuchka Yaroslav)

Nordic Pharma Inc, a subsidiary of Nordic Group BV, is presenting data on Lacrifill canalicular gel, a novel therapy for dry eye symptoms, during the American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting in April 5 to 8 in Boston, Massachusetts.

According to the company, the canalicular gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

Charlotte Phelps, CEOof Nordic Pharma, said in the news release the company is nearing the US launch of Lacrifill Canalicular Gel, “a key milestone in our global expansion strategy.”

“The recent acquisition of Visant Medical along with AmringPharmaceuticals becoming Nordic Pharma Inc, has increased our internal know-how andassets,” she added. “And with our strong US leadership team and the invaluable support of our medical advisory board, I firmly believe that Nordic Pharma is well-positioned to thrive as a new specialty ophthalmic player and enhance patient care by introducing this novel therapy for dry eye."

Eric D. Donnenfeld, MD, serves on the Lacrifill US Medical Advisory Board.

"As chairperson of the Lacrifill US Medical Advisory Board, I am excited about the potential of employing a cross-linked hyaluronic lacrimal filler to optimally occlude the canalicular system to maximize tear film preservation in patients with dry eye symptoms” he said in the news release.

During ASCRS, the company will highlight the canalicular gel and attendees will be able to place orders for the product. The gel also will be featured during sessions during Refractive and Cornea Subspeciality Day.

A panel, titled “Lacrifill: A Paradigm Shift in Dry Eye Intervention” will be held on Saturday, April 6, and will include Donnenfeld; PreeyaGupta, MD; Darrell White, MD; and Kevin J. Corcoran, COE, CPC, CPMA, FNAO and the principal of Corcoran & Corcoran.

Mark Packer, MD, FACS, CPI, will be moderating the panel.

“As a lacrimal filler, cross-linked hyaluronic acid provides a new approach to preservation of the tear film, protecting and conforming to delicate tissues while blocking outflow,” he said in the news release. “Lacrifill canalicular gel transforms treatment of the ocular surface, with demonstrated safety and effectiveness for both signs and symptoms of dry eye.”

Jai Parekh, MD, MBA, chief commercial officer of Eye Care US, also will present data on the gel.

“I am thrilled for Nordic Pharma to be presenting data on Lacrifill canalicular gel at a meeting as important as ASCRS,” he said in the news release. “This is where science and innovation come together, making it the perfect environment to highlight this novel therapy for dry eye.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.